The deals cover development and commercialization of next-generation sequencing and digital PCR assays for minimal residual disease detection.

Northwestern Medical will begin using PathAI's AISight digital pathology image management system as part of the deal.

Last week, readers were most interested in a story about what's up Roche's sleeve as it talked about its plans during its investor day.

The BLIPI test device was used to monitor babies' immune status from a drop of whole blood and detected sepsis within 15 minutes, enabling incubator-side testing.

Of the 30 companies included in the list, 15 saw their stock prices decline, while 15 saw their share prices rise.

The RiskReveal assay was used to determine which early-stage non-squamous NSCLC patients should undergo adjuvant chemotherapy.

Investors and consultants in the space said that they have seen rising enthusiasm among investors as recent funding rounds ...

The firm touted new assays, provided an update on its nanopore sequencer, and offered insights into upcoming pipeline ...

The firm's diagnostics and life sciences revenues jumped 8 percent, and Agilent raised its full-year guidance on expectations of 3 to 5 percent growth.

The team developed a tumor-independent test that is used to evaluate genome-wide cell-free DNA fragmentation profiles and repeat landscapes.

The firm presented data at AACR that showed the test had high accuracy when distinguishing ovarian cancer at early stages.